Phylodynamics of HIV-1 from a phase-III AIDS vaccine trial in North America

Molecular Biology and Evolution

Volumn 27, Issue 2, 2010, Pages 417-425

  Pérez Losada, Marcos ^a   Jobes, David V ^b   Sinangil, Faruk ^c   Crandall, Keith A ^d   Posada, David ^e   Berman, Phillip W ^f  

^a CENTRO DE INVESTIGAÇÃO EM BIODIVERSIDADE E RECURSOS GENÉTICOS   (Portugal)

^b Presidio Pharmaceuticals Inc   (United States)

^c Global Solutions for Infectious Diseases   (United States)

^d BRIGHAM YOUNG UNIVERSITY   (United States)

^e UNIVERSITY OF VIGO   (Spain)

^f University of California Santa Cruz   (United States)

Author keywords

America; Demographics; Gp120; HIV 1; Vaccine trial

Indexed keywords

GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; PLACEBO; UNCLASSIFIED DRUG; VAX 004;

ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED STUDY; DATA BASE; GENETIC VARIABILITY; GEOGRAPHIC DISTRIBUTION; HEALTH SURVEY; HEPATITIS B; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; NORTH AMERICA; PHASE 3 CLINICAL TRIAL; PHYLOGENY; RACE; SEQUENCE ANALYSIS; VACCINATION; VIRUS LOAD;

AIDS VACCINES; CLINICAL TRIALS, PHASE III AS TOPIC; HIV ENVELOPE PROTEIN GP120; HIV-1; HUMANS; NORTH AMERICA; PHYLOGENY; POPULATION DYNAMICS;

CERCOPITHECINE HERPESVIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 74549175896     PISSN: 07374038     EISSN: 15371719     Source Type: Journal    
DOI: 10.1093/molbev/msp254     Document Type: Article

References (45)

1. Akaike H. 1974. A new look at the statistical model identification. IEEE Trans Automat Contr. 19:716-723.
2. Castresana J. 2000. Selection of conserved blocks from multiple alignments for their use in phylogenetic analysis. Mol Biol Evol. 17:540-552.
3. Chohan B, Lang D, Sagar M, Korber B, Lavreys L, Richardson B, Overbaugh J. 2005. Selection for human immunodeficiency virus type 1 envelope glycosylation variants with shorter V1-V2 loop sequences occurs during transmission of certain genetic subtypes and may impact viral RNA levels. J Virol. 79:6528-6531.
4. Clark SJ, Saag MS, Decker WD, Campbell-Hill S, Roberson JL, Veldkamp PJ, Kappes JC, Hahn BH, Shaw GM. 1991. High titers of cytopathic virus in plasma of patients with symptomatic primary HIV-1 infection. New Engl J Med. 324:954-960.
5. Daar ES, Moudgil T, Meyer RD, Ho DD. 1991. Transient high levels of viremia in patients with primary human immunodeficiency virus type 1 infection. New Engl J Med. 324:961-964.
6. Derdeyn CA, Decker JM, Bibollet-Ruche F, et al. (14 co-authors). 2004. Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission. Science 303:2019-2022.
7. Drummond AJ, Ho SYW, Phillips MJ, Rambaut A. 2006. Relaxed phylogenetics and dating with confidence. PLoS Biol. 4:e88.
8. Drummond AJ, Rambaut A. 2007. BEAST: Bayesian evolutionary analysis by sampling trees. BMC Evol Biol. 7:214.
9. Drummond AJ, Rambaut A, Shapiro B, Pybus OG. 2005. Bayesian coalescent inference of past population dynamics from molecular sequences. Mol Biol Evol. 22:1185-1192.
10. Felsenstein J. 1985. Confidence limits on phylogenies: an approach using the bootstrap. Evolution 39:783-791.
11. Ferrante P, Delbue S, Mancuso R. 2005. The manifestation of AIDS in Africa: an epidemiological overview. J Neurovirol. 11(Suppl 1):50-57.
12. Fiebig EW, Wright DJ, Rawal BD, et al. (11 co-authors). 2003. Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS. 17:1871-1879.
13. Flynn NM, Forthal DN, Harro CD, Judson FN, Mayer KH, Para MF. 2005. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis. 191:654-665.
14. Gilbert MT, Rambaut A, Wlasiuk G, Spira TJ, Pitchenik AE, Worobey M. 2007. The emergence of HIV/AIDS in the Americas and beyond. Proc Natl Acad Sci USA. 104:18566-18570.
15. Gray ES, Moore PL, Choge IA, et al. (13 co-authors). 2007. Neutralizing antibody responses in acute human immunodeficiency virus type 1 subtype C infection. J Virol. 81:6187-6196.
16. Jaffe HW, Darrow WW, Echenberg DF, et al. (11 co-authors). 1985. The acquired immunodeficiency syndrome in a cohort of homosexual men. A six-year follow-up study. Ann Intern Med. 103:210-214.
17. Jobes DV, Daoust M, Nguyen V, Padua A, Michele S, Lock MD, Chen A, Sinangil F, Berman PW. 2006. High incidence of unusual cysteine variants in gp120 envelope proteins from early HIV type 1 infections from a phase 3 vaccine efficacy trial. AIDS Res Hum Retrovir. 22:1014-1021.
18. Katoh K, Kuma K, Toh H, Miyata T. 2005. MAFFT version 5: improvement in accuracy of multiple sequence alignment. Nucleic Acids Res. 33:511-518.
19. Keele BF, Giorgi EE, Salazar-Gonzalez JF, et al. (37 co-authors). 2008. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci USA. 105:7552-7557.
20. Korber B, Muldoon M, Theiler J, Gao F, Gupta R, Lapedes A, Hahn BH, Wolinsky S, Bhattacharya T. 2000. Timing the ancestor of the HIV-1 pandemic strains. Science 288:1789-1796.
21. Kosakovsky Pond SL, Frost SDW. 2005. Not so different after all: a comparison of methods for detecting amino acid sites under selection. Mol Biol Evol. 22:1208-1222.
22. Kosakovsky Pond SL, Frost SDW, Muse SV. 2005. HyPhy: hypothesis testing using phylogenies. Bioinformatics 21:676-679.
23. McVean G, Awadalla P, Fearnhead P. 2002. A coalescent-based method for detecting and estimating recombination from gene sequences. Genetics 160:1231-1241.
24. Oelrichs RB, Crowe SM. 2003. The molecular epidemiology of HIV-1 in South and East Asia. Curr HIV Res. 1:239-248.
25. Ou CY, Takebe Y, Weniger BG, Luo CC, Kalish ML, Auwanit W, Yamazaki S, Gayle HD, Young NL, Schochetman G. 1993. Independent introduction of two major HIV-1 genotypes into distinct high-risk populations in Thailand. Lancet. 341: 1171-1174.
26. Papathanasopoulos MA, Hunt GM, Tiemessen CT. 2003. Evolution and diversity of HIV-1 in Africa\-a review. Virus Genes. 26:151-163.
27. Peeters M, Toure-Kane C, Nkengasong JN. 2003. Genetic diversity of HIV in Africa: impact on diagnosis, treatment, vaccine development and trials. AIDS. 17:2547-2560.
28. Pérez-Losada M, Posada D, Arenas M, Jobes DV, Sinangil F, Berman PW, Crandall KA. 2009. Ethnic differences in the adaptation rate of HIV gp120 from a vaccine trial. Retrovirology 6:67.
29. Posada D, Crandall KA. 1998. Modeltest: testing the model of DNA substitution. Bioinformatics 14:817-818.
30. Quinn TC, Wawer MJ, Sewankambo N, Serwadda D, Li C, Wabwire-Mangen F, Meehan MO, Lutalo T, Gray RH. 2000. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. New Engl. J Med. 342:921-929.
31. Rambaut A, Drummond AJ. 2003. Tracer: MCMC trace analysis tool. University of Oxford, Oxford. Available from: http://evolve.zoo.ox. ac.uk.
32. R Development Core Team. 2008. R: a language and environment for statistical computing. R Foundation for Statistical Computing. Austria, Vienna. Available from: http://www.R-project.org.
33. Richman DD, Wrin T, Little SJ, Petropoulos CJ. 2003. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci USA. 100:4144-4149.
34. Ronquist F, Huelsenbeck JP. 2003. MrBayes 3: Bayesian phyloge-netic inference under mixed models. Bioinformatics 19: 1572-1574.
35. Shankarappa R, Margolick JB, Gange SJ, et al. (12 co-authors). 1999. Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection. J Virol. 73:10489-10502.
36. Stevens CE, Taylor PE, Zang EA, Morrison JM, Harley EJ, Rodriguez de Cordoba S, Bacino C, Ting RC, Bodner AJ, Sarngadharan MG. 1986. Human T-cell lymphotropic virus type III infection in a cohort of homosexual men in New York City. JAMA. 255:2167-2172.
37. Tavaré S. 1986. Some probabilistic and statistical problems in the analysis of DNA sequences. In: Miura RM, editor. Some mathematical questions in biology\-DNA sequence analysis. American Mathematical Society, Providence (RI). 17p. 57-86.
38. Tessier SF, Remy G, Louis JP, Trebucq A. 1993. The frontline of HIV1 diffusion in the Central African region: a geographical and epidemiological perspective. Int J Epidemiol. 22:127-134.
39. Tibayrenc M. 2005. Bridging the gap between molecular epidemiologists and evolutionists. Trends Microbiol. 13:575-580.
40. UNAIDS. 2008. Report on the global HIV/AIDS epidemic. Joint United Nations programme on HIV/AIDS (UNAIDS) 2008.
41. WHO Library Cataloguing-in-Publication Data, Geneva (Switzerland). 362. Watterson GA.
42. 1975. On the number of segregating sites in genetical models without recombination. Theor Popul Biol. 7:256-276.
43. Wei X, Decker JM, Wang S, et al. (15 co-authors). 2003. Antibody neutralization and escape by HIV-1. Nature 422: 307-312.
44. Weniger BG, Takebe Y, Ou CY, Yamazaki S. 1994. The molecular epidemiology of HIV in Asia. AIDS. 8(Suppl 2):S13-S28.
45. Zwickl DJ. 2006. Genetic algorithm approaches for the phylogenetic analysis of large biological sequence datasets under the maximum likelihood criterion. The University of Texas at Austin, Austin (TX). Available from: http://www.bio.utexas.edu/ faculty/antisense/garli/Garli.html